The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.
News|Videos|September 19, 2025
First-Line Tagraxofusp in BPDCN: Subgroup Analyses by Age and Fitness
Author(s)Naveen Pemmaraju, MD
Naveen Pemmaraju, MD, reviews subgroup analyses of tagraxofusp as first-line therapy in BPDCN, highlighting durable responses and successful transplant bridging across age and fitness groups
Advertisement
The program was sponsored by Menarini Stemline. The content was independently created by OncLive
Advertisement
Related to this article
A European Commission decision on belzutifan plus lenvatinib in pretreated advanced ccRCC is expected within 2 months, based on LITESPARK-011 data.
The phase 3 4WARD trial is evaluating mavorixafor for reducing infection rates and raising neutrophil counts in patients with primary chronic neutropenia.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Age, geographic location, transportation barriers, and language and communication barriers may limit patient opportunities to participate in research.
Targeting two alternate pathways at the same time led to improved outcomes in multiple preclinical models of advanced breast cancer.
Updated LEGEND cohort 1 data showed a 56% CR rate and a 24% 12-month CR rate with detalimogene in BCG-unresponsive, high-risk NMIBC with CIS.
Phase 2 Co-PSMA data showed higher lesion detection with 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11 in biochemical recurrence after prostatectomy.
Advertisement
Advertisement
Trending on OncLive
1
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
2
Dr Levy on Where Iza-Bren May Fit Following Osimertinib In EGFR-Mutated NSCLC
3
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
4
Dr Levy on How the EGFR-Targeted Therapy Landscape Has Evolved in NSCLC
5